Publications
Publications
Show Results For
- All HBS Web
(117,452)
- Faculty Publications (34)
←
Page 2 of 34
Results
- August 2023
- Case
Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company
By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
- August 2023 (Revised May 2024)
- Case
Dicerna Pharmaceuticals: Decision Making in Clinical Trial Design and Operations
By: Satish Tadikonda and Amanda McEwen
The success or failure of Dicerna Pharmaceuticals (Dicerna) as an emerging pharmaceutical company would likely hinge on its lead drug candidate Nedosiran and the company’s ability to see it successfully through clinical development. Ralf Rosskamp, Chief Medical... View Details
- August 2023 (Revised January 2024)
- Case
Jake Becraft and Strand Therapeutics: The Making of an Entrepreneur
By: Satish Tadikonda, William Marks and Ananya Zutshi
Jake Becraft, a PhD student at MIT disillusioned in pursuit of his dreams of becoming an academic, serendipitously finds himself discussing the potential commercial applications of his work with Tasuku Kitada, his former postdoctoral research mentor. The two decide to... View Details
- August 2023 (Revised January 2024)
- Case
Three Vignettes of Early Careers in the Life Sciences
By: Satish Tadikonda, Jacqueline Grant and William Marks
- August 2023
- Background Note
A Note on the Differences Between Therapeutics, Medical Devices, and Diagnostics
By: Satish Tadikonda, Ananya Zutshi, Hunter Goble and William Marks
- August 2023
- Teaching Note
Moderna: Everything, Everywhere, All at Once
By: Satish Tadikonda, Shikhar Ghosh and William Marks
Teaching Note for HBS Case No. 824-021. View Details
- August 2023 (Revised May 2024)
- Case
Morphic Therapeutic: Making the Initial Pipeline Decisions
By: Satish Tadikonda and Ananya Zutshi
- August 2023 (Revised August 2023)
- Case
Sky Therapeutics: Innovating in Digital Therapeutics
By: Satish Tadikonda, Olivia Reszczynski and William Marks
Shad Faraz and Alex Youssef were intrigued by the opportunities in the relatively new area of Digital Therapeutics. Despite initial successes, early entrants had struggled with reimbursement and revenue-predictability challenges. However, venture investors still... View Details
- July 2023
- Case
HealthVerity: Real World Data and Evidence
By: Satish Tadikonda
Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma... View Details
- July 2023 (Revised July 2024)
- Case
Miracle Therapeutics: Negotiating an IP License (A)
By: Satish Tadikonda, Michael Singer, William Marks and Wendi Yajnik
(General Experience Case) Beth Sharp and Jennifer Brilliant founded Miracle Therapeutics based on intellectual property developed by Brilliant and her post-doctoral student, John Supreme, in Brilliant’s lab at Elite University (EU). Miracle will have to obtain a... View Details
- July 2023
- Case
Moderna: Everything, Everywhere, All at Once
By: Satish Tadikonda, Shikhar Ghosh and William Marks
Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold... View Details
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company... View Details